RNS

Released : February 03, 2021 16:36   RNS Number : 9191N MaxCyte, Inc. 03 February 2021   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY
Feb 03, 2021
Released : February 03, 2021 16:35   RNS Number : 9190N MaxCyte, Inc. 03 February 2021   MaxCyte, Inc. (" MaxCyte " or the " Company ")    Appointment of Joint Corporate Broker   Gaithersburg, Maryland - 3 February 2021: MaxCyte (LSE: MXCT, MXCL), a global cell-engineering and life sciences company
Feb 03, 2021
Released : January 21, 2021 14:49   RNS Number : 5100M MaxCyte, Inc. 21 January 2021           MaxCyte, Inc. ("MaxCyte" or the "Company")     Increase to Block Listing,   Block Listing Return   and   Total Voting Rights       MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life
Jan 21, 2021
Released : January 20, 2021 07:00 RNS Number : 2360M MaxCyte, Inc. 20 January 2021                                               MaxCyte, Inc. ("MaxCyte" or the "Company")   Trading Update   ·      Full-year revenues at $26.2m  (21% growth over FY 2019) and second half revenue at $15.3m (15% over
Jan 20, 2021
Released : January 11, 2021 07:00   RNS Number : 1564L MaxCyte, Inc. 11 January 2021           Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs   Myeloid to utilize MaxCyte's Flow Electroporation ® technology and ExPERT ™
Jan 11, 2021
Released : December 23, 2020 07:00   RNS Number : 6024J MaxCyte, Inc. 23 December 2020   TRADING UPDATE  MaxCyte to exceed 2020 Full Year market expectations    Gaithersburg, Maryland  - 23 December 2020:  MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today
Dec 23, 2020
Released : November 09, 2020 13:00   RNS Number : 6703E MaxCyte, Inc. 09 November 2020           CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting     Gaithersburg, Maryland - 9 November 2020: MaxCyte, Inc.
Nov 09, 2020
Released : November 09, 2020 07:00   RNS Number : 5929E MaxCyte, Inc. 09 November 2020               MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences     Gaithersburg, MD , 9 November 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences
Nov 09, 2020
Released : November 02, 2020 15:52   RNS Number : 9956D MaxCyte, Inc. 02 November 2020             Result of AGM   Gaithersburg, Maryland - 02 November 2020:   MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, announces that at its Annual General Meeting held on 30
Nov 02, 2020
Released : October 22, 2020 18:22   RNS Number : 9790C MaxCyte, Inc. 22 October 2020             Disclosure of Remuneration for Non-Audit Services   Gaithersburg, Maryland - 22 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an
Oct 22, 2020